The Latest Breaking News on Pharma

EMA says relocation of sex workers to area near its HQ could bring problems associated with red light district

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

Reporter Sean Morrow wants to make sure credit goes to lawmakers working on drug pricing, Graig Graziosi reports

Walgreens says it will not start selling an abortion pill in 20 states that had warned of legal consequences if it did that

Kala Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 83.

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…